|Articles|December 1, 2019
- Pharmaceutical Executive-12-01-2019
- Volume 39
- Issue 12
Pharmaceutical Executive, December 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive December 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Market Access: Employers as Barriers to Valuealmost 6 years ago
Lundbeck's Taj Bhardwaj: Market Access and Mental Healthalmost 6 years ago
The Route to Market Access in Europealmost 6 years ago
A Multi-Stakeholder Perspective On Assessing Drug Valuealmost 6 years ago
When the Patient Loses in Market Accessalmost 6 years ago
Making Sense of Copay Accumulatorsalmost 6 years ago
Year in Review: R&D, Regulatory, and Reimbursement Hurdlesalmost 6 years ago
Who’s Going to Choose Where to Launch a Drug?almost 6 years ago
Back to the Basics?almost 6 years ago
Focus Report: Puerto RicoNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
